Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (9)

2016

  1. Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?

    European Journal of Pain (United Kingdom), Vol. 20, Núm. 3, pp. 472-482

2014

  1. Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: Data from the randomized, double-blind, COMBO-DN study

    Pain, Vol. 155, Núm. 10, pp. 2171-2179

2005

  1. Safety and effectiveness of olanzapine in monotherapy: A multivariate analysis of a naturalistic study

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 29, Núm. 6, pp. 944-951

  2. Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: A multivariate analysis of a large naturalistic study in the hospital setting

    Medicina Clinica, Vol. 124, Núm. 13, pp. 481-486

2003

  1. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 27, Núm. 3, pp. 473-481

  2. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study

    European Neuropsychopharmacology, Vol. 13, Núm. 1, pp. 39-48

2001

  1. Fluoxetine in the prevention of depressive recurrences: A double-blind study

    Journal of Clinical Psychopharmacology, Vol. 21, Núm. 4, pp. 417-424

1997

  1. Análisis coste-efectividad de olanzapina frente a haloperidol en el tratamiento de la esquizofrenia en España

    Actas Espanolas de Psiquiatria, Vol. 25, Núm. 4, pp. 225-234

1991

  1. Fluoxetine vs. clomipramine in depressed patients: a controlled multicentre trial

    Journal of Affective Disorders, Vol. 22, Núm. 3, pp. 119-124